

Supplementary Table 1: Comparison of clone EP1 and the SP1 in the *Oncotype* DX TMA set by cores

Intensity (Int)				
Int	SP1	%	EP1	%
0	17	5.5	22	7.1
1	24	7.7	15	4.8
2	131	42.1	89	28.6
3	139	44.7	185	59.5

Percentage (%)				
%	SP1	%	EP1	%
0	17	5.5	22	7
1-10	10	3.2	8	2.6
>10	284	91.3	281	90.4

Total score (TS)				
*TS	SP1	%	EP1	%
0	17	5.5	22	7
1-10	8	2.6	6	1.9
>10	286	91.9	283	91.1

*Total score obtained by combining intensity and percentage

Supplementary Table 2: Comparison of clone EP1 and the SP1 in the *Oncotype* DX TMA set by cases

Intensity (Int)				
Int	SP1		EP1	
0	6	3.4	7	4
1	10	5.7	6	3.4
2	69	39.2	49	27.8
3	91	51.7	114	64.8

Percentage (%)				
%	SP1	%	EP1	%
0	6	3.4	7	3.9
1-10	5	2.8	2	1.1
>10	165	93.8	167	95

Total score (TS)				
*TS	SP1	%	EP1	%
0	6	3.4	7	3.9
1-10	3	1.7	1	0.6
>10	167	94.9	168	95.5

*Total score obtained by combining intensity and percentage

Supplementary Table 3: Comparison of clone EP1 and the SP1 in the long-term followup TMA set by cores

Intensity (Int)				
Int	SP1	%	EP1	%
0	195	31.6	179	29
1	81	13.1	74	12
2	230	37.3	178	28.9
3	111	18	186	30.2

Percentage (%)				
%	SP1	%	EP1	%
0	195	31.6	179	29
1-10	43	6.9	47	7.6
>10	379	61.5	391	63.4

Total score (TS)				
*TS	SP1	%	EP1	%
0	195	31.6	179	29
1-10	37	6	40	6.5
>10	385	62.4	398	64.5

*Total score obtained by combining intensity and percentage

Supplementary Table 4: Comparison of clone EP1 and the SP1 in the long-term followup TMA set by cases

Intensity (Int)				
Int	SP1	%	EP1	%
0	102	26.2	97	24.9
1	50	12.9	42	10.8
2	153	39.3	118	30.3
3	84	21.6	132	33.9

Percentage (%)				
%	SP1	%	EP1	%
0	102	26.2	97	24.9
1-10	28	7.2	24	6.2
>10	259	66.6	268	68.9

Total score (TS)				
*TS	SP1	%	EP1	%
0	102	26.2	97	24.9
1-10	24	6	19	4.9
>10	263	67.7	273	70.2

*Total score obtained by combining intensity and percentage